Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
Cardiac toxicity in breast cancer treated with doxorubicin and paclitaxel
November 24th, 2005
Cardiac toxicity in breast cancer could be treated with neoadjuvant doxorubicin and paclitaxel (AT). "The psychological difficulty of accepting a mastectomy for locally advanced breast cancer (LABC) justifies the use of chemotherapy as neoadjuvant primary treatment. The aim of this prospective study was to assess the efficacy of the AT schedule neoadjuvantly administered in terms of response rates and survival in patients with LABC, with a special focus on cardiac toxicity," scientists in Belgium reported. "All patients were treated by doxorubicin (60 mg/m2 i.v.) bolus followed by paclitaxel (200 mg/m2) as a 3-h infusion....
Source: Women's Health Weekly (2005-11-24)
|
